BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31009664)

  • 1. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 3. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
    J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
    Harada T; Nakamura H
    Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
    [No Abstract]   [Full Text] [Related]  

  • 8. Tofacitinib Treatment for Pretibial Myxedema.
    Wang S; Chen X; Bai J; Sun Q; Fang H; Qiao J
    JAMA Dermatol; 2024 May; 160(5):578-580. PubMed ID: 38568614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 11. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
    Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
    An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK; Cernea M; Lynde CW
    Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of tofacitinib for refractory Behçet's syndrome.
    Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
    Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
    Chen LC; Ogbutor C; Kelley KJ; Senna MM
    J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical and Maintenance Treatments for Vitiligo.
    Passeron T
    Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.